[go: up one dir, main page]

MX2007006018A - Suspension farmaceutica oral novedosa de cristal de cefdinir. - Google Patents

Suspension farmaceutica oral novedosa de cristal de cefdinir.

Info

Publication number
MX2007006018A
MX2007006018A MX2007006018A MX2007006018A MX2007006018A MX 2007006018 A MX2007006018 A MX 2007006018A MX 2007006018 A MX2007006018 A MX 2007006018A MX 2007006018 A MX2007006018 A MX 2007006018A MX 2007006018 A MX2007006018 A MX 2007006018A
Authority
MX
Mexico
Prior art keywords
oral pharmaceutical
pharmaceutical suspension
novel oral
cefdinir
cefdinir crystal
Prior art date
Application number
MX2007006018A
Other languages
English (en)
Inventor
Naozumi Ohnishi
Satoshi Kitamura
Shuhei Deguchi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2007006018A publication Critical patent/MX2007006018A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/22—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with radicals containing only hydrogen and carbon atoms, attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se relaciona con una suspension farmaceutica oral novedosa de cristal de Cefdinir. De manera mas especifica, la presente invencion se relaciona con un equipo novedoso para la preparacion de una suspension farmaceutica oral que contiene la forma C cristalina de Cefdinir.
MX2007006018A 2004-11-30 2005-11-29 Suspension farmaceutica oral novedosa de cristal de cefdinir. MX2007006018A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63162804P 2004-11-30 2004-11-30
PCT/JP2005/022249 WO2006059753A1 (en) 2004-11-30 2005-11-29 Novel oral pharmaceutical suspension of cefdinir crystal

Publications (1)

Publication Number Publication Date
MX2007006018A true MX2007006018A (es) 2007-06-07

Family

ID=35809563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007006018A MX2007006018A (es) 2004-11-30 2005-11-29 Suspension farmaceutica oral novedosa de cristal de cefdinir.

Country Status (3)

Country Link
US (2) US7351419B2 (es)
MX (1) MX2007006018A (es)
WO (1) WO2006059753A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20020913A0 (it) * 2002-04-29 2002-04-29 Acs Dobfar Spa Nuova forma cristallina del cefdinir
AU2003255424A1 (en) 2002-08-13 2004-03-03 Sandoz Ag A cefdinir intermediate
CN100357294C (zh) * 2003-03-24 2007-12-26 桑多斯股份公司 7－[2－(2－氨基噻唑－4－基)－2－羟基亚氨基乙酰胺－3－乙烯基－3－头孢烯－4－羧酸(顺式异构体)的新型晶体和其制备方法
US20060211676A1 (en) * 2004-03-16 2006-09-21 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
MX2007006018A (es) * 2004-11-30 2007-06-07 Astellas Pharma Inc Suspension farmaceutica oral novedosa de cristal de cefdinir.
EP1828208A2 (en) * 2005-10-31 2007-09-05 Teva Pharmaceutical Industries Ltd Crystalline form of cefdinir cesium salt
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
CN103497204B (zh) * 2013-10-10 2016-03-23 珠海金鸿药业股份有限公司 一种头孢地尼化合物，其分散片及制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409214A (en) * 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
GB8323034D0 (en) * 1983-08-26 1983-09-28 Fujisawo Pharmaceutical Co Ltd 7-substituted-3-vinyl-3-cephem compounds
JPS62206199A (ja) 1986-03-07 1987-09-10 大竹　章 避難カプセル
ZA885709B (en) 1987-08-19 1989-04-26 Fujisawa Pharmaceutical Co Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid(syn isomer)
ES2175167T3 (es) 1995-12-27 2002-11-16 Hanmi Pharmaceutical Co Ltd Procedimiento para la preparacion de cefdinir.
AT405283B (de) * 1997-04-04 1999-06-25 Biochemie Gmbh Neues kristallines 7-(z)-(2-(2-aminothiazol-4-yl) -2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4- carbonsäure dicyclohexylammoniumsalz und verfahren zu dessen herstellung
PE20000879A1 (es) 1998-04-29 2000-09-23 Dsm Nv METODO PARA CRISTALIZAR UN ANTIBIOTICO ß-LACTAMICO
US20050060070A1 (en) * 2000-08-18 2005-03-17 Nnt, Inc. Wireless communication framework
KR100451672B1 (ko) * 2001-06-05 2004-10-08 한미약품 주식회사 결정성 세프디니르 산부가염, 이의 제조방법 및 이를이용한 세프디니르의 제조방법
RS52410B (sr) * 2001-09-26 2013-02-28 Merck Sharp & Dohme Corp. Postupak izrade jedinjenja karbapenema
AU2002347539A1 (en) * 2001-12-13 2003-06-23 Ranbaxy Laboratories Limited Crystalline cefdinir potassium dihydrate
US20060040915A1 (en) * 2002-04-26 2006-02-23 Yatendra Kumar Process for the preparation of cefdinir
ITMI20020913A0 (it) * 2002-04-29 2002-04-29 Acs Dobfar Spa Nuova forma cristallina del cefdinir
AU2003255424A1 (en) 2002-08-13 2004-03-03 Sandoz Ag A cefdinir intermediate
ITMI20022076A1 (it) 2002-10-01 2004-04-02 Antibioticos Spa Sali di intermedi del cefdinir.
WO2004046154A1 (en) 2002-11-15 2004-06-03 Orchid Chemicals & Pharmaceuticals Ltd Novel amorphous hydrate of a cephalosporin antibiotic
ITMI20022724A1 (it) * 2002-12-20 2004-06-21 Antibioticos Spa Sali cristallini del cefdinir.
AU2002368505A1 (en) * 2002-12-26 2004-07-22 Lupin Limited Novel intermediates for synthesis of cephalosporins and process for preparation of such intermediates
CN100357294C (zh) * 2003-03-24 2007-12-26 桑多斯股份公司 7－[2－(2－氨基噻唑－4－基)－2－羟基亚氨基乙酰胺－3－乙烯基－3－头孢烯－4－羧酸(顺式异构体)的新型晶体和其制备方法
CA2519272C (en) * 2003-03-27 2010-06-08 Basilea Pharmaceutica Ag Cephalosporin in crystalline form
WO2004104010A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Crystalline form of cefdinir
US20050137182A1 (en) * 2003-06-02 2005-06-23 Ramesh Dandala Novel crystalline form of cefdinir
US20040242556A1 (en) * 2003-06-02 2004-12-02 Ramesh Dandala Novel crystalline form of cefdinir
US7105659B2 (en) * 2003-06-02 2006-09-12 Aurobind - Pharma Ltd. Process for preparing cefdinir
WO2005019227A1 (en) * 2003-08-22 2005-03-03 Orchid Chemicals & Pharmaceuticals Ltd Process for the preparation of cephalosporin antibiotic
US20050059818A1 (en) * 2003-09-12 2005-03-17 Duerst Richard W. Polymorph of a pharmaceutical
BR0318535A (pt) 2003-09-30 2006-09-12 Lupin Ltd composição farmacêutica para o envio controlado de droga, processo para a preparação de uma composição farmacêutica e composição de liberação controlada
US20050119244A1 (en) * 2003-12-02 2005-06-02 Acs Dobfar S.P.A. Process for preparing cephalosporins with salified intermediate
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
US20060211676A1 (en) * 2004-03-16 2006-09-21 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060025399A1 (en) * 2004-03-16 2006-02-02 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060142261A1 (en) * 2004-03-16 2006-06-29 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060142563A1 (en) * 2004-03-16 2006-06-29 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
US20050215781A1 (en) * 2004-03-17 2005-09-29 Orchid Chemicals & Pharmaceuticals Ltd. Novel polymorph of cefdinir
WO2005090360A1 (en) 2004-03-19 2005-09-29 Orchid Chemicals & Pharmaceuticals Limited Novel polymorph of cefdinir
US20060029674A1 (en) * 2004-04-09 2006-02-09 Sever Nancy E Stable amorphous Cefdinir
US20060069079A1 (en) * 2004-09-27 2006-03-30 Sever Nancy E Stable amorphous cefdinir
US20050245738A1 (en) * 2004-05-03 2005-11-03 Lupin Ltd Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof
WO2006010978A1 (en) 2004-06-30 2006-02-02 Wockhardt Limited Cefdinir polymorphic forms, and imidazole salt
WO2006018807A1 (en) 2004-08-16 2006-02-23 Ranbaxy Laboratories Limited Crystalline forms of cefdinir
WO2006035291A1 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Crystalline forms of cefdinir potassium
MX2007006018A (es) 2004-11-30 2007-06-07 Astellas Pharma Inc Suspension farmaceutica oral novedosa de cristal de cefdinir.
GB2421024A (en) * 2004-12-07 2006-06-14 Sandoz Ag Cefdinir crystalline form C

Also Published As

Publication number Publication date
WO2006059753A1 (en) 2006-06-08
US20060135500A1 (en) 2006-06-22
US7351419B2 (en) 2008-04-01
US20070021402A1 (en) 2007-01-25
US7307072B2 (en) 2007-12-11

Similar Documents

Publication Publication Date Title
TW200508201A (en) Novel process for the preparation of roflumilast
TW200745114A (en) Novel compounds
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MX2009005461A (es) N-oxidos de analogos de 4,5-epoxi-morfinano.
TNSN08024A1 (en) 7-substituted aza-indazoles, compositions containing same, production method and use thereof
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
TW200616995A (en) Novel compounds
WO2006049734A3 (en) Quetiapine analogs and methods of use thereof
NZ527867A (en) Oral pharmaceutical composition of cefpodoxime proxetil
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
SI1511489T1 (sl) Novi farmacevtski sestavki, ki vsebujejo polimorf A flibanserina
MX2007003032A (es) Analogos de loxapina y metodos de uso de los mismos.
PL1758852T3 (pl) Podstawione związki cyklopentenu
MX2007006018A (es) Suspension farmaceutica oral novedosa de cristal de cefdinir.
TW200635917A (en) Novel compounds
TW200745122A (en) New compounds I
TW200605888A (en) Novel compounds
PL1507531T3 (pl) Trwałe kompozycje farmaceutyczne desloratadyny
TW200728310A (en) Process for the preparation of ferri-succinylcasein

Legal Events

Date Code Title Description
FG Grant or registration